OCGN
BEARISHAt a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
AI-powered fundamental assessment
Key Strengths
Key Risks
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Valuation is entirely based on future speculation rather than current assets or earnings.
- Price/Sales ratio of 144.89 is unsustainable
- Negative Price/Book ratio
- No Graham Number available due to negative earnings/equity
Future outlook relies on binary clinical/regulatory success rather than organic growth.
- Aggressive analyst price targets
- Forward P/E indicates a path to earnings
- Q/Q Revenue growth of -125.26%
- Year-over-Year EPS growth of -20.0%
Long-term trend is destructive despite short-term volatility spikes.
- Strong 1-year price recovery
- 5-year change of -66.3%
- Consistent history of earnings misses
Financial health is critical; the company is burning capital with negative equity.
- Current ratio slightly above 1.0
- Piotroski F-Score of 3/9 (Weak)
- ROE of -776.89%
- Quick ratio below 1.0 (0.81)
Not a dividend-paying security.
- No dividend history
- 0/100 dividend strength
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for OCGN and closest competitors.
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
OCGN
Ocugen, Inc.
Primary
|
-66.3% | +137.8% | +179.0% | +16.8% | -16.3% | +4.8% |
|
PROK
ProKidney Corp.
Peer
|
-78.4% | -83.2% | +175.6% | -26.6% | +4.8% | +11.8% |
|
AVNS
Avanos Medical, Inc.
Peer
|
-72.6% | -56.0% | -17.1% | +9.0% | +14.8% | +6.1% |
|
RIGL
Rigel Pharmaceuticals, Inc.
Peer
|
-6.8% | +165.8% | +92.5% | +16.1% | +27.5% | +11.1% |
|
ESPR
Esperion Therapeutics, Inc.
Peer
|
-91.3% | +70.1% | +119.8% | -9.3% | -23.4% | -10.7% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability
Profit margins and return metrics
Growth
Revenue and earnings growth rates
Financial Health
Balance sheet strength and liquidity metrics
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Quarterly Earnings History
EPS performance vs analyst estimates
Healthcare Sector Comparison
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
OCGN
Ocugen, Inc.
|
BEARISH | $639.4M | - | -776.9% | -% | $1.95 | |
|
PROK
ProKidney Corp.
|
BEARISH | $656.69M | - | -43.2% | -% | $2.18 | Compare |
|
AVNS
Avanos Medical, Inc.
|
BEARISH | $607.62M | - | -46.7% | -67.0% | $13.09 | Compare |
|
RIGL
Rigel Pharmaceuticals, Inc.
|
BULLISH | $599.31M | 1.66 | 185.9% | 124.7% | $32.43 | Compare |
|
ESPR
Esperion Therapeutics, Inc.
|
NEUTRAL | $598.37M | - | -% | -5.6% | $2.33 | Compare |
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-04-01 | ZHANG JUNGE | Director | Option Exercise | 194,134 | $154,303 |
| 2026-01-02 | MUSUNURI SHANKAR PH.D | Chief Executive Officer | Stock Award | 3,123,201 | - |
| 2026-01-02 | RAMACHANDRAN RAMESH | Officer | Stock Award | 207,300 | - |
Wall Street Analysts
Professional analyst ratings and price targets
Past News Coverage
Recent headlines mentioning OCGN from our newsroom.